Alnylam Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Alnylam Pharmaceuticals has a total shareholder equity of $250.6M and total debt of $2.5B, which brings its debt-to-equity ratio to 985.3%. Its total assets and total liabilities are $4.6B and $4.3B respectively.
Key information
985.35%
Debt to equity ratio
US$2.47b
Debt
| Interest coverage ratio | n/a |
| Cash | US$2.86b |
| Equity | US$250.59m |
| Total liabilities | US$4.32b |
| Total assets | US$4.57b |
Recent financial health updates
Recent updates
Need To Know: Analysts Are Much More Bullish On Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Aug 01
Alnylam: Amvuttra Is Just Getting Started
Jul 31We Take A Look At Why Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) CEO Has Earned Their Pay Packet
May 01Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster
Mar 21Alnylam: Waiting For Regulatory Updates In March
Feb 13Is Alnylam Pharmaceuticals (NASDAQ:ALNY) A Risky Investment?
Jan 17What Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) P/S Is Not Telling You
Dec 16Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch
Oct 27Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?
Sep 12Alnylam: HELIOS-B Success Priced In Already
Aug 30RNAi: Winning In The Clinic, Now For The Market
Jun 25Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation
Jun 03Is Alnylam's HELIOS-B Delay A Red Flag?
Mar 10Alnylam's Huge Opportunity
Jan 12Financial Position Analysis
Short Term Liabilities: ALNY's short term assets ($3.6B) exceed its short term liabilities ($1.3B).
Long Term Liabilities: ALNY's short term assets ($3.6B) exceed its long term liabilities ($3.0B).
Debt to Equity History and Analysis
Debt Level: ALNY has more cash than its total debt.
Reducing Debt: ALNY's debt to equity ratio has increased from 72.5% to 985.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALNY has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ALNY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/18 18:32 |
| End of Day Share Price | 2025/08/18 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alnylam Pharmaceuticals, Inc. is covered by 67 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Huidong Wang | Barclays |
| Emily Bodnar | Berenberg |